🔗 Share this article

A shadow economy for unlicensed slimming drugs is being driven by social media fitness personalities and vendors on messaging platforms, according to new investigations.

Experimental Drug Acquiring Popularity Via Social Media

The experimental drug, which remains in clinical trials, is being promoted by online personalities for its alleged weight-reducing properties. Viewers are urged to message these accounts privately for supplier links, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Additionally, a flourishing trade exists on Telegram, where groups with thousands of members share “before and after” images, administration instructions and assertions of next-day UK delivery. Sellers market the substance there before directing buyers to other platforms for purchases.

Learning About The Experimental Drug

This medication is an experimental injection created by American pharmaceutical company Eli Lilly. The drug affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials indicate it could assist patients reduce up to 25% of their body weight. Nicknamed the “triple G”, the drug is being promoted online as the next Ozempic.

Medical Experts Express Concerns

Nevertheless, doctors and pharmacists have warned that the distribution of what is still an unapproved medication in the UK is a cause for concern and could result in individuals injecting substances of unknown origin.

Some professionals said the demand for retatrutide could be connected to the increasing cost of approved weight loss treatments such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or Telegram is prohibited in the United Kingdom, as it is an unlicensed medication that cannot be marketed or supplied for human use under the British medical regulations.

Some content creators attempt to circumvent the regulations by referring to the drug as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but promotion and distribution can still breach pharmaceutical, advertising, and consumer regulations, risking fines, legal action or imprisonment.

Service Response and Material Removal

Based on TikTok, the service has taken down problematic material and banned associated keywords and query recommendations. The company said it was committed to keeping the platform secure and investing in strengthening enforcement strategies.

Digital Marketplace Operations

Research also discovered groups with up to 9,000 participants selling the experimental drug using the platform's built-in discovery tool, which operates like a public directory. Typing “retatrutide” instantly brings up groups with numerous of users, filled with images of slimming results, positive reviews and step-by-step instructions for mixing or administering at home.

After minutes of entering one community, a seller posted contact information, where the majority of transactions take place. The seller provided an guidebook and guaranteed delivery within two days. When questioned whether the product was genuine, one seller responded: “You can’t be sure.” Another provided a image of a supposed laboratory certificate. Not one asked about weight, medical conditions or previous experience.

Product Information and Costs

Inside these groups, posts display black plastic packages with postal service stickers, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at home with sterile water, or pre-filled pens usually priced at 160 pounds for 20mg. When questioned how long a pen should be used, sellers give conflicting responses varying between a several days to “depends on your body”.

Platform Oversight and Security Measures

A spokesperson for the messaging service stated it actively monitored harmful content on its service including material that encouraged the “misuse of controlled medications”. The company added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are injecting materials they can’t verify. Although the research behind retatrutide is valid, these online products may not contain what they claim,” said a pharmacy expert, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the surge in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With prices increasing, individuals are turning to online platforms. But fake injections are highly risky. You cannot know what’s inside or whether the environment they were produced in was clean,” she explained.

Her staff has already encountered patients harmed by self-injection from unverified sources. “We recognize the frustration, but buying from messaging apps or communication platforms is taking chances with your health,” stated Wyllie. “These substances could be contaminated or improperly measured.”

Manufacturer Statement

A representative from Eli Lilly stated retatrutide was in third stage clinical trials and had not been evaluated or authorized by any government authority globally. “Therefore at this point no one can market [it] for personal consumption,” they said, adding that any item “falsely representing itself as a company experimental product not yet authorized … may expose users to possibly serious medical dangers”.